At a recent NIH study section that I chaired, we had many applications that we reviewed as a group before the meeting. At the meeting, we were required to discuss over 50% of the grants.
In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL).
